ArticleScientific reports2020
Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Trial
- Correlation of serum CTRP9 and CTRP15 levels with HOMA-IR and HOMA-B in metabolic syndrome patients with and without coronary artery disease.Pakistan journal of medical sciences · 2026Article
- Unveiling the roles of CTRP family in cardiac remodeling.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Genetic Evidence of Causal Effect between C1q/TNF-Related Protein-1 and Atherosclerosis: a Bidirectional and Multivariate Mendelian Randomization Study.Journal of atherosclerosis and thrombosis · 2025Article
- Predictive Potential of CRTP5 and SII for Coronary Artery Severity and Myocardial Fibrosis in Patients with NSTE-ACS: An Exploratory Biomarker Study.Journal of inflammation research · 2025Article
- Serum levels of C1q/TNF-related protein-1 (CTRP1) and CTRP3 in patients with coronary artery disease.ARYA atherosclerosis · 2025Article
- Late-Onset Retinal Degeneration: Clinical Features and C1QTNF5/CTRP5 Function.Advances in experimental medicine and biology · 2025Review
- Multicomponent comprehensive confirms that erythroferrone is a molecular biomarker of pan-cancer.Heliyon · 2024Article
- Circulating erythroferrone has diagnostic utility for acute decompensated heart failure in patients presenting with acute or worsening dyspnea.Frontiers in cardiovascular medicine · 2023Article
- Deletion of large-conductance calcium-activated potassium channels promotes vascular remodelling through the CTRP7-mediated PI3K/Akt signaling pathway.Acta biochimica et biophysica Sinica · 2022Article
- Where all the Roads Meet? A Crossover Perspective on Host Factors Regulating SARS-CoV-2 infection.Journal of molecular biology · 2022Review
- Role of serum C1q/TNF-related protein family levels in patients with acute coronary syndrome.Frontiers in cardiovascular medicine · 2022Article
- Association of serum and aqueous humor myonectin concentrations with diabetic retinopathy.Scientific reports · 2021Article
- C1q Complement/Tumor Necrosis Factor-Associated Proteins in Cardiovascular Disease and COVID-19.Proteomes · 2021Review
- Circulating CTRP7 Is a Potential Predictor for Metabolic Syndrome.Frontiers in endocrinology · 2021Article
- Decreased serum myonectin concentrations in diabetic nephropathy patients.Clinical and experimental medicine · 2020Article
- Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases.Frontiers in cardiovascular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The C1q complement/TNF-related protein superfamily (CTRPs) displays differential effects on the regulation of metabolic homeostasis, governing cardiovascular function. However, whether and how they may serve as predictor/pro-diagnosis factors for assessing the risks of coronary artery disease (CAD) remains controversial. Therefore, we performed a clinical study to elaborate on the implication of CTRPs (CTRP1, CTRP5, CTRP7, and CTRP15) in CAD. CTRP1 were significantly increased, whereas CTRP7 and CTRP15 levels were decreased in CAD patients compared to the non-CAD group. Significant differences in CTRP1 levels were discovered between the single- and triple-vascular-vessel lesion groups. ROC analysis revealed that CTRP7 and CTRP15 may serve as CAD markers, while CTRP1 may serve as a marker for the single-vessel lesion of CAD. CTRP1 and CTRP5 can serve as markers for the triple-vessel lesion. CTRP1 may serve as an independent risk predictor for triple-vessel lesion, whereas CTRP15 alteration may serve for a single-vessel lesion of CAD. CTRP1 may serve as a novel superior biomarker for diagnosis of severity of vessel-lesion of CAD patients. CTRP7, CTRP15 may serve as more suitable biomarker for the diagnosis of CAD patients, whereas CTRP5 may serve as an independent predictor for CAD. These findings suggest CTRPs may be the superior predictive factors for the vascular lesion of CAD and represent novel therapeutic targets against CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.